Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25443768 | 0.86 | SMN1; SMN2 (0.46) | ROCK2ROCK1PIK3CDSMN1; SMN2HTT | |
| SCHEMBL23842223 | 0.83 | CYP2D6 (0.48) | PIK3CDSMN1; SMN2HTTALDH1A1CYP2D6 | |
| SCHEMBL14551445 | 0.82 | HTT (0.36) | SMN1; SMN2HTTKCNH2KDM4ECCR5 | |
| SCHEMBL23986335 | 0.81 | CARM1 (0.36) | KCNH2PARP1BACE1 | |
| SCHEMBL21472222 | 0.80 | HRH3 (0.38) | ROCK2ROCK1PIK3CDHRH3CYP2D6 | |
| SCHEMBL16553909 | 0.79 | PIK3CD (0.41) | ROCK2ROCK1PIK3CDSMN1; SMN2HRH3 | |
| SCHEMBL2760188 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2KCNH2KDM4EALDH1A1CCR5 | |
| SCHEMBL23696209 | 0.78 | ROCK2 (0.43) | ROCK2ROCK1PIK3CDSMN1; SMN2HTT | |
| SCHEMBL24508277 | 0.78 | ROCK2 (0.40) | ROCK2ROCK1PIK3CDSMN1; SMN2HTT | |
| SCHEMBL22856522 | 0.77 | CYP2D6 (0.45) | PIK3CDSMN1; SMN2ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ROCK2 2938/4885ROCK1 2753/4885PIK3CD 321/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | ROCK2 4052/4885ROCK1 4363/4885PIK3CD 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.